<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: It has been suggested that preoperative administration of erythropoietin (Epo) in patients with <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancer</z:e> reduces transfusional needs and is also associated with lower morbidity </plain></SENT>
<SENT sid="1" pm="."><plain>On the other hand, experimental and clinical studies show that Epo might enhance <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Our aim was to ascertain whether preoperative administration of Epo has any effect on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence after curative surgery using an experimental model of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIALS AND METHODS: We induced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> by injecting B51LiM <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells into the cecal wall of Balb/c mice </plain></SENT>
<SENT sid="4" pm="."><plain>We randomized the animals into three groups of treatment with (1) recombinant human Epo, (2) recombinant mouse Epo, or (3) vehicle alone, for 12 d until cecectomy </plain></SENT>
<SENT sid="5" pm="."><plain>On postoperative day 12, we killed mice and analyzed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence </plain></SENT>
<SENT sid="6" pm="."><plain>We measured serum levels of vascular endothelial growth factor and determined vascular endothelial growth factor expression and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microvessel density by immunohistochemistry </plain></SENT>
<SENT sid="7" pm="."><plain>We also investigated the inÂ vitro effect of Epo on B51LiM cell line proliferation </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> three groups displayed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence, but the final <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> load score and total tumoral weight were higher in the two groups that included Epo </plain></SENT>
<SENT sid="9" pm="."><plain>The differences were statistically significant when we compared the recombinant mouse Epo group with the control group </plain></SENT>
<SENT sid="10" pm="."><plain>We found no evidence of <z:mp ids='MP_0005601'>increased angiogenesis</z:mp> or enhanced cell proliferation as possible mechanisms of Epo-induced recurrence </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Preoperative administration of Epo stimulates <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence in an animal model of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Our results point to the need for further research on the mechanisms of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> enhancement by Epo, to better understand the benefits or disadvantages of Epo treatment </plain></SENT>
</text></document>